2 results
Not approvedWill not start
The objectives of this study are to demonstrate that Nepafenac Ophthalmic Suspension, 0.3% is not inferior to Nepafenac Ophthalmic Suspension, 0.1% (NEVANAC®); Nepafenac Ophthalmic Suspension, 0.3% is superior to Nepafenac 0.3% Vehicle and NEVANAC…
Approved WMORecruiting
The primary efficacy objective is to determine the effect of NCAP on the clinical signs and symptoms of rheumatoid arthritis as assessed by the 28 Joint Disease Activity Score (DAS28).The secondary efficacy objectives are to determine the effect of…